PP

Pawan Pandey

Director Director DIN 08919635
DIN 08919635 First appointment Oct 2020 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Oct 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Pawan Pandey

Data last updated:

Pawan Pandey was a Director at Viprans Drug And Pharmaceuticals Private Limited (2020–2021) and Director at Viprans Consulting Private Limited (from 2020). The companies operate in Chemicals.

DIN 08919635
Primary Designation Director
Industry Chemicals
First Appointment 12 Oct 2020
Oldest Company Age 13 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director03 Nov 20202020₹2 Lakh (FY 2022)Strike Off
Viprans Consulting Private Limited U74140MP2013PTC031199
Director12 Oct 20202013₹88,598 (FY 2018)Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Viprans Consulting Private Limited
Viprans Drug And Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Pawan Pandey

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pawan Pandey

Pawan Pandey was first appointed on 12 Oct 2020 as Director at Viprans Consulting Private Limited.

Pawan Pandey held 2 earlier board appointments: Viprans Drug And Pharmaceuticals Private Limited (Director, 03 Nov 2020 to 28 Aug 2021); Viprans Consulting Private Limited (Director, from 12 Oct 2020).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available